HFpEF, or heart failure with preserved ejection fraction, is treated through a combination of medications, lifestyle changes, and aggressive management of the conditions that drive it. Unlike heart failure with a reduced ejection fraction, where several drug classes have decades of strong evidence, HFpEF treatment has historically been more about controlling symptoms and coexisting problems. That changed in recent years with the arrival of SGLT2 inhibitors, which are now the closest thing to a proven disease-modifying therapy for this condition.
HFpEF means your heart pumps out a normal percentage of blood with each beat (an ejection fraction of 50% or higher) but has become stiff or otherwise impaired, making it harder to fill properly and causing fluid to back up. The result is the same shortness of breath, fatigue, and swelling that other forms of heart failure produce.
SGLT2 Inhibitors: The Strongest Evidence
SGLT2 inhibitors are the treatment with the most robust data behind them for HFpEF. The 2022 AHA/ACC heart failure guidelines give them a Class 2a recommendation, meaning they are considered beneficial for reducing heart failure hospitalizations and cardiovascular death. In practice, many cardiologists now treat them as a first-line medication for HFpEF alongside diuretics and blood pressure control.
The landmark EMPEROR-Preserved trial, published in the New England Journal of Medicine, tested empagliflozin against placebo in nearly 6,000 patients over about two years. Patients taking empagliflozin had a 21% lower risk of the combined outcome of cardiovascular death or hospitalization for heart failure. The benefit was driven primarily by a 29% reduction in heart failure hospitalizations. These drugs were originally developed for type 2 diabetes, but their heart failure benefits appear to work independently of blood sugar control. They help the body shed excess sodium and fluid through the kidneys, reduce the workload on the heart, and appear to have direct protective effects on heart muscle.
Managing Fluid Overload With Diuretics
Congestion, the buildup of fluid that causes swelling in the legs, abdominal bloating, and breathlessness, is the primary driver of symptoms in HFpEF. Loop diuretics are the first-line therapy for relieving this congestion. The most commonly prescribed is furosemide, typically started at 20 to 40 mg once daily for outpatients. Maintenance doses range from 40 mg to 240 mg daily depending on how much fluid your body is retaining. If more than 80 mg per day is needed, splitting the dose between morning and midday works better than taking it all at once.
The goal is to reach a stable, comfortable fluid balance and then taper to the lowest dose that keeps you there. For people who are on optimal therapy, haven’t been hospitalized recently, and are taking 80 mg or less of furosemide, it may even be possible to stop the diuretic entirely under medical supervision. Daily weight checks are the simplest way to track fluid status at home. A sudden gain of two or more pounds overnight usually signals fluid retention.
Blood Pressure Control
Treating high blood pressure is the only Class 1 (strongest) recommendation in the current guidelines for HFpEF. Uncontrolled hypertension makes the heart muscle thicker and stiffer over time, which is the central problem in HFpEF. A target of less than 130/80 mmHg is supported by the available evidence for people with symptomatic heart failure and hypertension. Several drug classes can get you there, including ACE inhibitors, ARBs, and calcium channel blockers, with the specific choice depending on your other medical conditions.
Other Medications With Possible Benefit
Several additional drug classes carry weaker recommendations for HFpEF, generally reserved for selected patients, particularly those whose ejection fraction sits closer to the lower end of the preserved range (around 45% to 55%).
- Mineralocorticoid receptor antagonists (spironolactone). The large TOPCAT trial of 3,445 patients produced mixed results overall. However, patients who were enrolled based on elevated levels of a blood marker called BNP (which indicates heart wall stress) saw a significant 35% reduction in the primary outcome. Those enrolled based on a prior hospitalization alone did not benefit. This suggests spironolactone may help a specific subset of HFpEF patients, particularly those with clear biomarker evidence of ongoing cardiac stress.
- ARBs (angiotensin receptor blockers). These may reduce hospitalizations, especially in patients on the lower end of the preserved ejection fraction spectrum. They also serve double duty as blood pressure medications.
- Sacubitril-valsartan (an ARNI). The PARAGON-HF trial of 4,822 patients narrowly missed its primary endpoint, showing a 13% reduction in hospitalizations and cardiovascular death that did not reach statistical significance. It may still be considered in selected patients, again particularly those with ejection fractions closer to 45% to 50%.
Treating Atrial Fibrillation
Atrial fibrillation and HFpEF frequently coexist, and managing the irregular rhythm is a Class 2a recommendation in the guidelines. A meta-analysis found that a rhythm control strategy (actively trying to restore and maintain a normal heart rhythm) was associated with a 27% lower risk of death compared to rate control (simply keeping the heart rate from going too fast while allowing the irregular rhythm to continue). This is a meaningful difference, and many specialists now favor rhythm control for HFpEF patients with atrial fibrillation. Catheter ablation is typically recommended for patients who remain symptomatic despite medication.
Weight Loss in Patients With Obesity
Obesity is one of the most common and impactful contributors to HFpEF. Excess body fat increases blood volume, raises filling pressures in the heart, and promotes inflammation. Newer GLP-1 receptor agonist medications have shown striking results in this population. The STEP-HFpEF trial tested semaglutide in patients with HFpEF and obesity. Over the study period, patients on semaglutide lost an average of 13.3% of their body weight compared to 2.6% with placebo. More importantly, their heart failure symptoms improved substantially: scores on a standardized quality-of-life questionnaire improved by 7.8 points more than placebo, a difference patients can feel in their daily activities, breathing, and energy levels.
Exercise Training
Structured exercise is one of the most effective non-drug treatments for HFpEF. It improves peak oxygen uptake, which is a direct measure of exercise capacity and one of the most reliable predictors of how heart failure patients feel day to day. The mechanism in HFpEF is different from other forms of heart failure. Rather than improving the heart’s pumping ability, exercise training in HFpEF works by improving the muscles’ ability to extract and use oxygen, along with changes in body composition and blood vessel function.
Moderate-intensity continuous exercise (like brisk walking, cycling, or swimming at a steady pace) appears to be the most practical approach. High-intensity interval training has not shown clear superiority for equivalent energy expenditure and tends to be harder for patients to stick with. Combining exercise with caloric restriction in patients who are overweight produces a synergistic effect on fitness that is greater than either intervention alone. Most cardiac rehabilitation programs run for 12 weeks, with sessions three to five times per week, and the improvements in exercise tolerance and quality of life are consistently demonstrated across studies.
Why Treating the Whole Picture Matters
HFpEF is not a single disease so much as a syndrome driven by multiple overlapping conditions. High blood pressure, obesity, diabetes, atrial fibrillation, kidney disease, and physical deconditioning all feed into the same stiff, congested heart. The most effective treatment plans address as many of these contributors as possible simultaneously. SGLT2 inhibitors and diuretics form the pharmacological backbone, blood pressure control is essential, and weight loss plus exercise provide benefits that medications alone cannot fully replicate. Each piece of the treatment plan targets a different part of the problem, and together they produce the largest improvements in symptoms and outcomes.